Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers

American Journal of Epidemiology

Volumn 172, Issue 1, 2010, Pages 81-93

  Stolzenberg Solomon, Rachael Z ^a   Jacobs, Eric J ^a   Arslan, Alan A ^a   Qi, Dai ^a   Patel, Alpa V ^a   Helzlsouer, Kathy J ^a   Weinstein, Stephanie J ^a   McCullough, Marjorie L ^a   Purdue, Mark P ^a   Shu, Xiao Ou ^a   Snyder, Kirk ^a   Virtamo, Jarmo ^a   Wilkins, Lynn R ^a   Yu, Kai ^a   Zeleniuch Jacquotte, Anne ^a   Zheng, Wei ^a   Albanes, Demetrius ^a   Cai, Qiuyin ^a   Harvey, Chinonye ^a   Hayes, Richard ^a   Clipp, Sandra ^a   Horst, Ronald L ^a   Irish, Lonn ^a   Koenig, Karen ^a   Le Marchand, Loic ^a   Kolonel, Laurence N ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Case control studies; Cohort studies; Pancreatic neoplasms; Prospective studies; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D;

BODY MASS; CANCER; COHORT ANALYSIS; DIABETES; EPIDEMIOLOGY; HEALTH RISK; PARTICIPATORY APPROACH; PUBLIC HEALTH; REGRESSION ANALYSIS; SMOKING; VITAMIN;

ADULT; AGED; ARTICLE; ASIAN; BODY MASS; CANCER RISK; CAUCASIAN; DIABETES MELLITUS; ETHNICITY; FEMALE; FOLLOW UP; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; RACE; SMOKING; VITAMIN BLOOD LEVEL; ADENOCARCINOMA; BLOOD; CASE CONTROL STUDY; CHINA; COHORT ANALYSIS; FINLAND; META ANALYSIS (TOPIC); MIDDLE AGED; PANCREAS TUMOR; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; UNITED STATES; VITAMIN D DEFICIENCY;

ADENOCARCINOMA; ADULT; AGED; CASE-CONTROL STUDIES; CHINA; COHORT STUDIES; FEMALE; FINLAND; HUMANS; LOGISTIC MODELS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 77956919944     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq120     Document Type: Article

References (49)

1. Grant WB. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int J Cancer. 2007;120(5):1123-1128.
2. Boscoe FP, Schymura MJ. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer. 2006;6:264. (doi: 10.1186/1471-2407-6-264).
3. Tuohimaa P, Pukkala E, Scélo G, et al. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. Eur J Cancer. 2007;43(11):1701-1712.
4. Mizoue T. Ecological study of solar radiation and cancer mortality in Japan. Health Phys. 2004;87(5):532-538.
5. Kinoshita S, Wagatsuma Y, Okada M. Geographical distribution for malignant neoplasm of the pancreas in relation to selected climatic factors in Japan. Int J Health Geogr. 2007; 6:34. (doi: 10.1186/1476-072X-6-34).
6. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer. 2002;94(6):1867-1875.
7. Neale RE, Youlden DR, Krnjacki L, et al. Latitude variation in pancreatic cancer mortality in Australia. Pancreas. 2009; 38(4):387-390.
8. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr. 2003;89(5):552-572.
9. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004;79(3):362-371.
10. Office of Dietary Supplements, National Institutes of Health Dietary Supplement Fact Sheet: Vitamin D. Bethesda, MD: National Institutes of Health; 2008.
11. 3-1α-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol. 2004;89-90(1-5):121-125.
12. 3-1α-hydroxylase. J Clin Endocrinol Metab. 2001;86(2):888-894.
13. 3. Carcinogenesis. 2004;25(6):1015-1026.
14. Zugmaier G, Jäger R, Grage B, et al. Growth-inhibitory effect of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer. 1996;73(11):1341-1346.
15. Pettersson F, Colston KW, Dalgleish AG. Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D ana logues on pancreatic cancer cells in vitro. Br J Cancer. 2000;83(2):239-245.
16. 2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cance Biol Ther. 2008;7(3):430-436.
17. 3 on the proliferation of pancreatic cancer cell lines. Gastroenterology. 1996;110(5): 1605-1613.
18. Mathieu C, Gysemans C, Giulietti A, et al. Vitamin D and diabetes. Diabetologia. 2005;48(7):1247-1257.
19. 3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J. 2000;47(4):383-391.
20. Maestro B, Dávila N, Carranza MC, et al. Identification of a vitamin D response element in the human insulin receptor gen promoter. J Steroid Biochem Mol Biol. 2003;84(2-3):223-230.
21. Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005;294(22):2872-2878.
22. Huxley R, Ansary-Moghaddam A, Berrington de González A et al. Type-II diabetes and pancreatic cancer: a meta-analysi of 36 studies. Br J Cancer. 2005;92(11):2076-2083.
23. Michaud DS, Wolpin B, Giovannucci E, et al. Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev. 2007;16(10): 2101-2109.
24. Hennig R, Ding XZ, Adrian TE. On the role of the islets of Langerhans in pancreatic cancer. Histol Histopathol. 2004; 19(3):999-1011.
25. Skinner HG, Michaud DS, Giovannucci E, et al. Vitamin D intake and the risk for pancreatic cancer in two cohort studies Cancer Epidemiol Biomarkers Prev. 2006;15(9):1688-1695.
26. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mor tality in men. J Natl Cancer Inst. 2006;98(7):451-459.
27. Stolzenberg-Solomon RZ, Vieth R, Azad A, et al. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res. 2006; 66(20):10213-10219.
28. Stolzenberg-Solomon RZ, Hayes RB, Horst RL, et al. Serum vitamin D and risk of pancreatic cancer in the Prostate, Lung, Colorectal, and Ovarian Screening Trial. Cancer Res. 2009; 69(4):1439-1447.
29. The ATBC Cancer Prevention Study Group. The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study: design, methods, participant characteristics, and compliance. Ann Epidemiol. 1994;4(1):1-10.
30. Helzlsouer KJ, Alberg AJ, Huang HY, et al. Serum concentrations of organochlorine compounds and the subsequent development of breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8(6):525-532.
31. Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer. 2002; 94(9):2490-2501.
32. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst. 1995;87(3): 190-197.
33. Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol. 2000;151(4):346-357.
34. Hayes RB, Sigurdson A, Moore L, et al. Methods for etiologic and early marker investigations in the PLCO Trial. Mutat Res. 2005;592(1-2):147-154.
35. Zheng W, Chow WH, Yang G, et al. The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. Am J Epidemiol. 2005;162(11):1123-1131.
36. Lee SA, Xu WH, Zheng W, et al. Physical activity patterns and their correlates among Chinese men in Shanghai. Med Sci Sports Exerc. 2007;39(10):1700-1707.
37. Wagner D, Hanwell HE, Vieth R. An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem. 2009;42(15):1549-1556.
38. Fears TR, Ziegler RG, Donaldson JL, et al. Reproducibility studies and interlaboratory concordance for and rogen assays in female plasma. Cancer Epidemiol Biomarkers Prev. 2000; 9(4):403-412.
39. Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses. Am J Epidemiol. 1986;124(1): 17-27.
40. Looker AC, Dawson-Hughes B, Calvo MS, et al. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone. 2002; 30(5):771-777.
41. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19(2):73-78.
42. Gallicchio L, Helzlsouer KJ, Chow W-H, et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):10-20.
43. Kimlin MG. The climatology of vitamin D producing ultraviolet radiation over the United States. J Steroid Biochem Mol Biol. 2004;89-90(1-5):479-483.
44. Holick MF. The use and interpretation of assays for vitamin D and its metabolites. J Nutr. 1990;120(suppl 11):1464-1469.
45. Zeleniuch-Jacquotte A, Gallicchio L, Hartmuller V, et al. Circulating 25-hydroxyvitamin D and risk of endometrial cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):36-46.
46. Platz EA, Leitzmann MF, Hollis BW, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control. 2004;15(3): 255-265.
47. Zhou C, Verma S, Blumberg B. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl Recept Signal. 2009;7e001. (doi: 10.1621/nrs.07001).
48. Gómez JM. The role of insulin-like growth factor I components in the regulation of vitamin D. Curr Pharm Biotechnol. 2006;7(2):125-132.
49. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Vitamin D. In: Dietary Reference Intakes: For Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academies Press; 1997:250-287.